L-MIND
The small single-arm study that got tafasitamab approved for people too frail for transplant.
ORR 60%, CR 43%; median DOR 43.9 months; median OS 33.5 months at 5 years. RE-MIND matched real-world comparison supported approval.
Setting
R/R DLBCL, transplant-ineligible, 1-3 prior lines: tafasitamab + lenalidomide (single arm)
Phase
Phase 2
Sponsor
MorphoSys
Registry
Headline result
ORR 60%, CR 43%.
Reported
2020
Enrolled
81
In plain words
What these results mean for people, not percentages
Objective response rateprimaryresponse endpoint
- 60 out of 100 people had their tumour shrink with Tafasitamab + lenalidomide.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: R/R DLBCL, transplant-ineligible, 1-3 prior lines: tafasitamab + lenalidomide (single arm). People in a different situation may not see the same effect.
- Only 81 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
81 participants enrolled.
Objective response rateprimary
Tafasitamab + lenalidomide60 of 100
n = 80
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rateprimary | Tafasitamab + lenalidomide | 80 | 60% | — | — | — |
Pages like this
not linked directly; found by shared links- TrialfrontMIND
Shares Tafasitamab, Lenalidomide, Diffuse large B-cell lymphoma.
- CompanyIncyte
Shares Tafasitamab, Diffuse large B-cell lymphoma.